PROCEPT BioRobotics Corp (PRCT) company profile

The company develops, manufactures, and sells image-guided surgical robotic systems for minimally invasive urology, focusing on treating benign prostatic hyperplasia. Its primary products are the AquaBeam Robotic System and the HYDROS Robotic System. Each system utilizes single-use disposable handpieces to deliver Aquablation therapy, combining ultrasound imaging, robotic automation, and heat-free waterjet ablation to remove prostate tissue. The company primarily sells its products to hospitals, as well as to ambulatory surgery centers, distribution partners, and leasing companies.

The company maintains an installed base of 912 robotic systems globally, including 718 units in the United States and the remainder internationally. It sells through a direct sales organization in the United States targeting urologists across approximately 2,700 hospitals. Internationally, sales occur through direct personnel and third-party distribution partners. The provided text does not mention the company's headquarters location.

Summary of the business section of PROCEPT BioRobotics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Per Share Total Initial public offering price $25.00 $163,900,000 Underwriting discounts and commissions (1) $1.75 $11,473,000 Proceeds, before expenses, to us $23.25 $152,427,000 __________ (1) See the section titled “Underwriting” for additional information regarding compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 888 employees.”